UK NSC Sets Out Stance on Surrogate Outcomes in Cancer Screening

The UK National Screening Committee (UK NSC) has published a position statement addressing the role of surrogate outcomes in adult cancer screening trials, according to a paper in the BMJ. The document is directed at screening test developers, researchers, and research funders.

What the UK NSC Does

The UK NSC advises the four UK governments on all aspects of systematic screening programmes, covering their introduction, modification, and cessation. Its recommendations emerge from a multicriteria assessment framework that weighs evidence on mortality and morbidity benefit alongside a range of other considerations, including potential harms, equity, acceptability, feasibility, and cost effectiveness.

A dedicated research and methodology group within the committee supports funders and researchers by advising on the evidence requirements needed to inform UK NSC recommendations.

The Case for and Against Cancer Screening

The statement acknowledges the dual nature of cancer screening. On one side, earlier detection and treatment can reduce both mortality and morbidity. On the other, screening programmes carry recognised risks: false positive results can cause unnecessary anxiety and follow-up procedures, while some cancers detected through screening may never have progressed to cause harm — a phenomenon known as overdiagnosis.

This tension between benefit and harm sits at the centre of how the UK NSC evaluates any proposed or existing programme, and it forms the backdrop against which the position statement on surrogate outcomes has been developed.

Surrogate Outcomes in Trial Design

In cancer screening research, surrogate outcomes — such as detection rates or stage at diagnosis — are sometimes used as proxies when long-term mortality data are not yet available. The UK NSC's statement sets out the committee's current assessment of the evidence in this area, offering a framework for how such measures should be interpreted and weighted in research intended to inform screening policy.

The document is described as guidance for shaping research design at an early stage, before definitive cancer mortality figures become accessible from trials.

Intended Audience

The BMJ paper makes clear that the position statement is not aimed at the general public or clinicians in routine practice. Instead, it is addressed specifically to those involved in developing, funding, or designing cancer screening research — a signal that the UK NSC is seeking to influence how future evidence is generated rather than how existing programmes are delivered.

The statement reflects the committee's broader role in shaping the evidence base that underpins national screening policy across the United Kingdom.